$INO

Today. Inovio Pharmaceuticals Inc. (NASDAQ:INO) was reiterated as Buy and its price target was raised to 17 from 13 at HC Wainwright after announcing promising MERS data that could set the stage for a potential COVID-19 vaccine. My work augurs for a run to 29/30+ if it happens.

This is a speculation, if you can manage the risk, take a shot, and if the stock 2Xs be prudent, sell half of the position and ride it for free.

Wednesday, INO finished at 13.74, -0.01, Vs its 52 wk high at 19.36 on higher than average volume. Key Support is at 8.45 and the Resistance is Nil. 3 of our Key technical indicators have turned Very Bullish, 1 long term.

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.

Its SynCon immunotherapy design has the ability to break the immune systems tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens.

The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).

Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agencys Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. Inovio Pharmaceuticals, Inc. was founded in Y 1979 and is HQd in Plymouth Meeting, Pennsylvania.

Have a healthy day, Keep the Faith!

immunology, INO, resistance, risk, stock, support, vaccine

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of The Red Roadmasters Technical Report on the US Major Market Indices, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

Continued here:
Sitting on a Pile of Cash? Here is Another Coronavirus Immunology Play, Take a Shot - Live Trading News